Literature DB >> 29679875

Impurity profiling of varenicline tartrate by LC-QTOF mass spectrometric techniques during drug development.

Yuting Lu1, Xiyang Sun1, Fan Song1, Lei Wang2, Min Song1, Taijun Hang3.   

Abstract

An LC-QTOF-MS method was developed for the separation and characterization of related substances in varenicline tartrate. The separation was established on an InertSustain C18 column (4.6 mm × 150 mm, 5 μm) by liner gradient elution using 0.05% trifluoroacetic acid as mobile phase A and acetonitrile as mobile phase B. The degradation studies were conducted under the ICH prescribed stress conditions. Varenicline tartrate was found to be unstable to alkaline, oxidative, thermal and photolytic stresses, while relatively stable under acid stress condition. Thirteen related substances were detected all together in varenicline tartrate and its stressed samples. Their structures were identified mainly through positive ESI high resolution QTOF mass spectrometric analysis of the parent and product ions' accurate masses and the calculated elemental compositions. Among the 13 related substances, seven were process-related and six were degradation products, and two of them were further verified by chemical synthesis and NMR spectroscopic determination. Their formation mechanisms were also discussed, and the key steps in the manufacturing processes were also determined to provide varenicline tartrate with high purity.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  LC-QTOF-MS; Related substancesRelated substances; Varenicline tartrate

Mesh:

Substances:

Year:  2018        PMID: 29679875     DOI: 10.1016/j.jpba.2018.03.055

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Spectroscopic strategies for quantitation of varenicline in pharmaceutical preparations and content uniformity testing.

Authors:  Fawzia Ibrahim; Rasha Aboshabana; Heba Elmansi
Journal:  R Soc Open Sci       Date:  2022-09-28       Impact factor: 3.653

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.